Company intelligence
Neuvasq Biotechnologies
Advancing innovative Wnt surrogate antibodies to restore blood-CNS barriers.
Biotechnology
Gosselies, BE
15 employees
Founded 2021
3 public signals
About Neuvasq Biotechnologies
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers. This groundbreaking approach holds the potential to transform treatments and improve the lives of patients with vascular retinopathies – diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) – or severe neurological disorders.
Verified activity
Signals from Neuvasq Biotechnologies
3 published signals
People
Neuvasq Biotechnologies welcomed Oya Yilmaz as a Research Associate to the drug discovery team.
Reported by Neuvasq Biotechnologies
Presence & Recognition
Neuvasq Biotechnologies is attending the European Brain Barriers Meeting 2026 on September 16–18 in Aarhus, Denmark to share insights on restoring neurovascular integrity and presenting its multispecific Gpr124-targeting antibodies.
Reported by Neuvasq Biotechnologies
Presence & Recognition
Neuvasq Biotechnologies presented its latest work at EBBM 2026.
Reported by Isabel Vogel